| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bromelain is a mixture of enzymes found in pineapples, particularly in the stem and fruit.
key points regarding bromelain and cancer: -Anti-Inflammatory Properties: -Immune System Support: -Direct Anticancer Effects: -Synergistic Effects with Chemotherapy: Biological activity, bromelain has been reported to exhibit a range of effects, including: Anti-inflammatory activity: 10-50 μM Antioxidant activity: 10-100 μM Anti-cancer activity: 50-100 μM Cardiovascular health: 20-50 μM Digestive health: 10-50 μM Cooking can affect the concentration of bromelain in pineapple. Heat can denature the enzymes, making them less active. The extent of the loss of activity depends on the temperature, cooking time, and method of cooking. For example: -Boiling or steaming pineapple for 10-15 minutes can reduce the bromelain activity by 50-70% -Baking or roasting pineapple at 350°F (30-40min) reduce the bromelain activity by 70-90% Bromelain — bromelain is a proteolytic enzyme complex derived mainly from pineapple stem, with lesser related fractions from fruit. It is best classified as a botanical protease mixture / natural product nutraceutical rather than a single defined small molecule. Standard abbreviations include bromelain and BML. Its functional identity is a cysteine-protease-rich mixture with anti-inflammatory, immunomodulatory, mucolytic, and context-dependent anticancer activity. In oncology, the most defensible interpretation is that bromelain is an experimental adjunct with preclinical antitumor and anti-metastatic signals, but without established mainstream systemic anticancer approval or definitive phase III evidence. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral bromelain shows limited but real absorption of intact enzymatically active material; circulating enzyme is partly bound by antiproteases such as α2-macroglobulin and α1-antichymotrypsin. This supports systemic biological plausibility, but exposure is constrained, heterogeneous, and not well standardized across products. As a protease mixture, batch composition and formulation materially affect PK relevance. In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use bromelain concentrations that are difficult to map directly onto human systemic exposure because bromelain is a heterogeneous enzyme mixture rather than a single analyte. Therefore, direct translation of cell-culture dose levels to oral human dosing is weak. Mechanistic plausibility exists, but potency in vitro likely overstates predictable systemic anticancer exposure from standard oral supplements. Clinical evidence status: Preclinical evidence is substantial. Human oncology evidence is limited and mostly adjunctive or exploratory, including small supportive studies on immune modulation or treatment side effects, plus early-phase mucinous-tumor work with BromAc rather than bromelain alone. No established standard-of-care systemic anticancer indication is supported at present. Mechanistic relevance in cancer
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Caspases are a cysteine protease that speed up a chemical reaction via pointing their target substrates following an aspartic acid residue.1 They are grouped into apoptotic (caspase-2, 3, 6, 7, 8, 9 and 10) and inflammatory (caspase-1, 4, 5, 11 and 12) mediated caspases. Caspase-1 may have both tumorigenic or antitumorigenic effects on cancer development and progression, but it depends on the type of inflammasome, methodology, and cancer. Catalase is an enzyme found in nearly all living cells exposed to oxygen. Its primary role is to protect cells from oxidative damage by catalyzing the conversion of hydrogen peroxide (H₂O₂), a potentially damaging byproduct of metabolism, into water (H₂O) and oxygen (O₂). This detoxification process is crucial because excess H₂O₂ can lead to the formation of reactive oxygen species (ROS) that damage proteins, lipids, and DNA. Catalase and Cancer Oxidative Stress and Cancer: Cancer cells often experience increased levels of oxidative stress due to rapid proliferation and metabolic changes. This stress can lead to DNA damage, promoting tumorigenesis. Catalase helps mitigate oxidative stress, and its expression can influence the survival and proliferation of cancer cells. Expression Levels in Different Cancers: Overexpression: In some cancers, such as breast cancer and certain types of leukemia, catalase may be overexpressed. This overexpression can help cancer cells survive in oxidative environments, potentially leading to more aggressive tumor behavior. Downregulation: Conversely, in other cancers, such as colorectal cancer, reduced catalase expression has been observed. This downregulation can lead to increased oxidative stress, contributing to tumor progression and metastasis. Prognostic Implications: Survival Rates: Studies have shown that high levels of catalase expression can be associated with poor prognosis in certain cancers, as it may enable cancer cells to resist apoptosis (programmed cell death) induced by oxidative stress. Some types of cancer cells have been reported to exhibit lower catalase activity, possibly increasing their vulnerability to oxidative damage under certain conditions. This vulnerability has even been exploited in some therapeutic strategies (for example, approaches that generate excess H₂O₂ or other ROS specifically targeting cancer cells have been researched). |
| 5680- | BML, | Anticancer properties of bromelain: State-of-the-art and recent trends |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:216 Target#:46 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid